

01-23-04

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/665,336	
	Filing Date	September 19, 2003	
	First Named Inventor	Michael D. Schneider	
	Art Unit	N/A	
	Examiner Name	Not Yet Assigned	
Total Number of Pages in This Submission	1	Attorney Docket Number	HO-P02514US3

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 29 References
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	FULBRIGHT & JAWORSKI L.L.P. Melissa W. Acosta
Signature	
Date	January 22, 2004


Transmittal

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. ER 147059908 US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: January 22, 2004

Signature:

(Annette Devereux)



I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail Airbill No. ER 147059908 US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: January 22, 2004

Signature:

Annette Devereux
(Annette Devereux)

Docket No.: HO-P02514US3
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Michael D. Schneider et al.

Application No.: 10/665,336

Confirmation No.:

Filed: September 19, 2003

Art Unit: N/A

For: MODULATORS OF CDK9 AS A
THERAPEUTIC TARGET IN CARDIAC
HYPERTROPHY

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A copy of each reference on the PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

Application No.: 10/665,336


Docket No.: HO-P02514US3

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-2375, under Order No. HO-P02514US3. A duplicate copy of this paper is enclosed.

Dated: January 22, 2004

Respectfully submitted,

By 

Melissa W. Acosta

Registration No.: 45,872


FULBRIGHT & JAWORSKI L.L.P.

1301 McKinney, Suite 5100

Houston, Texas 77010-3095

(713) 651-5151

(713) 651-5246 (Fax)



PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
				Application Number	10/665,336
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Filing Date	September 19, 2003
				First Named Inventor	Michael D. Schneider
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	HO-P02514US3
Sheet	1	of	2		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US-6043254	03-28-2000	Grell et al.	
	AB	US-5604251	02-18-1997	Heitsch et al.	
	AC	US-6399633	06-04-2002	Dumont et al.	
	AD	US-6201165	03-13-2001	Grant et al.	


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO-9833791-A1	08-06-1998	Bristol-Myers Squibb Company		
	BB	WO-0113900-A2	03-01-2001	Medicure, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Abdellatif et al, "A Ras-Dependent Pathway Regulates RNA Polymerase II Phosphorylation in Cardiac Myocytes: Implications for Cardiac Hypertrophy," Molecular and Cellular Biology, November 1998, pp. 6729-6736.	
	CB	Adams et al, "Enhanced Gq α Signaling: A Common Pathway Mediates cardiac Hypertrophy and Apoptotic Heart Failure," Proc. Natl. Acad. Sci. USA, Vol. 95, August 1998, pp. 10140-10145.	
	CC	Akhtar et al., "Distinct Activated and Non-Activated RNA Polymerase II Complexes in Yeast," The Embo Journal Vol. 15 No. 17, 1996, pp. 4654-4664.	
	CD	Bueno et al, "The MEK1-ERK1/2 Signaling Pathway Promotes Compensated Cardiac Hypertrophy in Transgenic Mice" The EMBO Journal Vol. 19 No. 23, 2000, pp. 6341-6350.	
	CE	Cho et al, "A Protein Phosphate Functions to Recycle RNA Polymerase II," Genes & Development Vol. 13, 1999, pp. 1540-1552.	
	CF	Chao et al, "Flavopiridol Inhibits P-TEFb and Blocks HIV-1 Replication," The Journal of Biological Chemistry Vol. 275, No. 37, September 15, 2000, pp. 28345-28348.	
	CG	Chao et al, "Flavopiridol Inactivates P-TEFb and Blocks Most RNA Polymerase II Transcription in Vivo," The Journal of Biological Chemistry Vol. 276, No. 34, August 24, 2001, pp. 31793-31799.	
	CH	Dahmus, Michael. "Reversible Phosphorylation of the C-terminal Domain of RNA Polymerase II," The Journal of Biological Chemistry Vol. 271, No. 32, August 9, 1996, pp. 19009-19012.	
	CI	Dietz et al., "Improvement of Cardiac Function by Angiotensin converting Enzyme Inhibition: Sites of Action," Circulation 1993; 87 [suppl IV]: IV-108-IV-116.	
	CJ	Esposito et al, "Genetic Alterations that Inhibit In Vivo Pressure-Overload Hypertrophy Prevent Cardiac Dysfunction Despite Increased Wall Stress," Circulation 2002; 105, pp 85-92.	
	CK	Fu et al, "Cyclin K Functions as a CDK9 Regulatory Subunit and Participates in RNA	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/665,336
				Filing Date	September 19, 2003
				First Named Inventor	Michael D. Schneider
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	HO-P02514US3
Sheet	2	of	2		

		Polymerase II Transcription," The Journal of Biology Chemistry Vol. 274 No. 49, December 3, 1999, pp. 34527-34530.	
	CL	Laporte et al, "Neointima Formation After Vascular Injury is Angiotensin II Mediated," Biochemical and Biophysical Research Communications Vol. 187 No. 3, September 30, 1992, pp. 1510-1516.	
	CM	Majello et al, "Control of RNA Polymerase II Activity by Dedicated CTD Kinases and Phosphatases," Frontiers in Bioscience 6, October 1, 2001, pp. 1358-1368.	
	CN	Molkentin et al., "Cytoplasmic Signaling Pathways that Regulate Cardiac Hypertrophy," Annu. Rev. Physiol. 63, 2001, pp. 391-426.	
	CO	Nguyen et al, "7SK Small Nuclear RNA binds to and Inhibits the Activity of CDK/(Cyclin T Complexes," Nature Vol. 414, November 15, 2001, pp. 322-325.	
	CP	Oh et al, "Telomerase Reverse Transcriptase Promotes Cardiac Muscle Cell Proliferation, Hypertrophy, and Survival," PNAS Vol. 98, No. 18, August 28, 2001, pp. 10308-10313.	
	CQ	Orphanides et al, "A Unified Theory of Gene Expression," Cell Vol. 108, February 22, 2002, pp. 439-451.	
	CR	Sano et al, "Cyclins That Don't Cycle: Cyclin T/Cyclin-Dependent Kinase-9 Determines Cardiac Muscle Cell Size," Cell Cycle 2:2, March/April 2003, pp. 99-104.	
	CS	Sano et al, "Activation and Function of Cyclin T-Cdk9 (positive transcription elongation factor-b) in Cardiac Muscle-Cell Hypertrophy," Nature Medicine Vol. 8, No. 11, November 2002, pp. 1310 - 1317.	
	CT	Shioi et al, "Akt/Protein Kinase B Promotes Organ Growth in Transgenic Mice," Molecular and Cellular Biology, April 2002, pp. 2799-2809.	
	CU	Shioi et al, "The conserved Phosphoinositide 3-Kinase Pathway Determines Heart Size in Mice," The EMBO Journal Vol. 19, No. 11, 2000, pp. 2537-2548.	
	CV	Yang et al, "The 7SK Small Nuclear RNA Inhibits the CDK9/Cyclin T1 Kinase to Control Transcription," Nature Vol. 414, November 15, 2001, pp. 317-321.	
	CW	Zhang, et al, "TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice," Nature Medicine Vol. 6 No. 5, May 2000, pp. 556-563.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



Application No. (if known): 10/665,336

Attorney Docket No.: HO-P02514US3

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. ER 147059908 US in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on January 22, 2004
Date

Signature

Annette Devereux

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant